IntegenX
Date | Investors | Amount | Round |
---|---|---|---|
$4.5m | Series A | ||
$18.1m | Series B | ||
$15.6m | Series B | ||
$40.0m | Series C | ||
$10.0m | Debt | ||
N/A | Acquisition | ||
Total Funding | $78.2m |
Related Content
Recent News about IntegenX
EditIntegenX specializes in providing advanced DNA analysis solutions designed for rapid human identification in forensic and clinical applications. The company serves law enforcement agencies, forensic laboratories, and healthcare providers, operating within the biotechnology and life sciences market. IntegenX's business model revolves around the development and sale of automated DNA identification systems, which significantly reduce the time required for DNA analysis from days to hours. Revenue is generated through the sale of these systems, as well as ongoing service and maintenance contracts. The company leverages cutting-edge technology to offer reliable and efficient solutions, enhancing the capabilities of its clients in solving crimes and improving patient care.
Keywords: DNA analysis, forensic identification, clinical applications, biotechnology, life sciences, automated systems, rapid identification, law enforcement, healthcare, technology-driven.